What You Should Know
– Carna Health has raised $8M to scale its AI-driven Cardio-Kidney-Metabolic (CKM) platform. The round included participation from Dr. Jay Rosan, Cenk Bekmezçi, Jose Pereyra, Mark Boulding, Brandon Salomon, Andrew Roosevelt, Jeff Lindsey, Joseph White, John Brooks, Elvis Ndansi and Dr. Salvatore Viscomi.
– Following a successful initiative in Cameroon that screened 35,000 individuals, Carna is expanding its partnership with Siemens Healthineers to bring point-of-care kidney testing to the Philippines and the Dominican Republic.
– The platform uses AI to identify early-stage Chronic Kidney Disease (CKD), providing accessible tools to prevent disease progression in diverse global infrastructures.
The “Silent Disease” Challenge: Closing the Identification Gap
Chronic Kidney Disease (CKD) is often called a “silent killer” because symptoms rarely appear until the late stages when dialysis or transplantation are the only remaining options. Carna Health addresses this by creating a low-friction screening infrastructure that works even in resource-limited environments.
- Global Scale: Following its success in Cameroon, Carna is launching initiatives in the Philippines and a national program in the Dominican Republic, with plans to enter the U.S. and Turkish markets shortly.
- Siemens Healthineers Integration: The partnership leverages Siemens’ global point-of-care diagnostics, allowing for laboratory-grade testing to be performed in community settings.
- AI-Driven Management: The platform doesn’t just screen; it uses AI to help clinicians navigate care pathways, ensuring that “at-risk” patients receive coordinated follow-up for related metabolic conditions.
“This funding enables us to continue global expansion, offering a transformative digital health platform that expands access to comprehensive chronic kidney disease (CKD) care. By integrating AI-driven solutions for early identification, monitoring, and patient management, we’re empowering patients and healthcare providers to navigate care pathways more effectively,” said Salvatore Viscomi, MD, Chief Executive Officer.
